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Abstract
The purpose of the present study was to identify noninvasive methods
to evaluate the severity of iron overload in transfusion-dependent
ß-thalassemia and the efficiency of intensive intravenous therapy as an
additional tool for the treatment of iron-overloaded patients. Iron
overload was evaluated for 26 ß-thalassemia homozygous patients,
and 14 of them were submitted to intensive chelation therapy with
high doses of intravenous deferoxamine (DF). Patients were classified
into six groups of increasing clinical severity and were divided into
compliant and non-compliant patients depending on their adherence
to chronic chelation treatment. Several methods were used as indica-
tors of iron overload. Total gain of transfusion iron, plasma ferritin,
and urinary iron excretion in response to 20 to 60 mg/day subcutane-
ous DF for 8 to 12 h daily are useful to identify iron overload; however,
urinary iron excretion in response to 9 g intravenous DF over 24 h and
the increase of urinary iron excretion induced by high doses of the
chelator are more reliable to identify different degrees of iron overload
because of their correlation with the clinical grades of secondary
hemochromatosis and the significant differences observed between
the groups of compliant and non-compliant patients. Finally, the use
of 3-9 g intravenous DF for 6-12 days led to a urinary iron excretion
corresponding to 4.1 to 22.4% of the annual transfusion iron gain.
Therefore, continuous intravenous DF at high doses may be an addi-
tional treatment for these patients, as a complement to the regular
subcutaneous infusion at home, but requires individual planning and
close monitoring of adverse reactions.
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Introduction
Conservative treatment of ß-thalassemia
is based on regular red cell transfusions to
maintain the hemoglobin levels close to nor-
mal (1). This, however, causes an excessive
iron build-up in the organism, culminating in
the installation of secondary hemochromato-
sis that causes endocrine, hepatic and car-
diac dysfunction (2-5). Long and worldwide
experience has proven the efficiency of pro-
phylaxis of iron overload based on the sub-
cutaneous infusion of deferoxamine (DF)
combined with oral vitamin C (1,4,6). Both
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Table 1. Clinical and laboratory features of the thalassemia patients.
Patient Age Weight Symptoms Spleen Compliant Glucose GTT ALT (U/l) HCV Cardiac Clinical
No. (years) (kg) (cm) (mg/dl) abnormalities grade
1 4 22 Absent 4 Yes 94 - 17.0 - - 0
2 4 20 Absent 3 Yes 83 - 42.5 - - I
3 5 18 Absent 3 Yes 84 - 60.9 - - I
4 5 20 Absent 3 Yes 96 - 50.0 - - I
5 6 22 Absent np Yes 83 - 20.0 + - 0
6 6 21 Absent np Yes 84 - 19.1 - - 0
7 9 29 Absent np Yes 105 Normal 27.2 - - 0
8 10 27 Absent np Yes 88 Normal 120.5 - - I
9 10 37 Absent 4 Yes 95 Normal 28.5 + - 0
10 12 44 Absent splx Yes 87 Normal 58.2 - + II
11 13 40 CHF np No 98 Normal 89.0 + ++ IV
12 13 29 Absent 1 No 85 Normal 66.0 + + II
13 13 39 Absent 3 Yes 89 Normal 25.0 - - 0
14 13 38 Absent splx No 86 Normal 84.5 - - I
15 14 41 Absent 3 Yes 97 Normal 28.2 + - 0
16 14 34 Absent np Yes 91 Normal 15.5 - + I
17 15 50 Absent splx Yes 98 Normal 22.0 - ++ II
18 16 49 Absent splx Yes 100 Normal 69.5 indeter - I
19 17 43 Bone deformity splx No 97 Normal 64.5 indeter ++ III
20 19 46 Bone deformity splx No 85 Normal 24.0 - ++ II
21 20 47 CHF and DM splx No 300/513 - 35.0 - + III
22 21 50 CHF and DM splx No 444/420 - 39.0 + ++ V
23 21 53 Bone deformity splx Yes 169/154 Diabetic 25.5 indeter ++ III
24 25 48 Bone deformity splx Yes 106 Normal 38.2 + ++ III
25 28 49 Bone deformity splx No 100 Normal 36.0 + + II
26* 50 57 Leg ulcers and splx No 92 Intolerant 43.0 + + III
bone deformity
CHF: congestive heart failure; DM: diabetes mellitus; spleen: measured below the costal margin; np: non-palpable; splx: splenectomy; GTT:
glucose tolerance test; ALT: alanine aminotransferase; HCV: anti-HCV antibody; indeter: indeterminate; cardiac abnormalities: see Table 2.
*Thalassemia intermedia.
clinical and laboratory data indicate the ben-
efits of this treatment (6-11) and an increase
in life expectancy of compliant patients (5,12-
14). Since many patients eventually develop
cardiac or endocrine complications, it has
been suggested that the addition of high
intravenous doses of DF may help prevent or
delay the development of hemochromatosis
(3,15,16).
The purpose of the present study was to
identify noninvasive methods to determine
the degree of iron overload in transfusion-
dependent ß-thalassemia homozygotes and
to evaluate the efficiency of a more intensive
therapeutic approach to induce excretion of
large quantities of iron as an additional tool
for the treatment of iron-overloaded patients.
Patients and Methods
Patients
The study included 26 transfusion-
dependent ß-thalassemia homozygotes (12
females and 14 males, 25 with thalassemia
major and one with thalassemia intermedia),
who had been under regular treatment for at
least three years at the Hemotherapy and
Hematology Service of the University Hos-
pital (Table 1). The study was reviewed and
approved by the Hospital Ethics Committee.
Since the beginning of treatment, all
thalassemia major patients were kept on a
transfusion regimen to maintain hemoglobin
levels above 10 g/dl, and iron chelation with
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subcutaneous DF (20 to 60 mg kg-1 day-1)
administered with a portable pump for 8 to
12 h daily, at least 5 days a week, and 100 mg
vitamin C daily. The thalassemia intermedia
patient developed complications late in life
and has been transfused regularly since the
end of the fourth decade of life.
On the basis of the information obtained
by questioning the patients and the families
on the occasion of every monthly visit, the
patients were divided into two groups: 17
compliant with treatment (patients who used
at least 80% of the prescribed DF dose) and
9 non-compliant patients (Table 1). Three
patients (patients 11, 21 and 22) had conges-
tive heart failure and two of them died (pa-
tients 11 and 22). Patients 21 and 22 also
presented the classical symptoms of diabe-
tes mellitus.
In addition to patients 21 and 22 who had
overt clinical diabetes mellitus, patient 23
fulfilled laboratory criteria for diabetes and
patient 26, with thalassemia intermedia, had
an “intolerant” glucose tolerance test, ac-
cording to the criteria of the National Diabe-
tes Data Group (17). All patients presented
normal prothrombin time (international nor-
malized ratio between 0.9 and 1.2), but 14
patients (53.8%) presented elevated serum
alanine aminotransferase (ALT). No patient
had a positive test for HBsAg but 34.6%
were positive for anti-hepatitis C virus (Table
1), and all patients were negative for anti-
HIV 1 and anti-HTLV 1 antibodies.
Evaluation of cardiac function (Table 2)
revealed that 6 patients (23.0%) had an en-
larged cardiac shadow in the chest X-ray, 9
patients (34.6%) had electrocardiographic
changes, and 10 patients (38.5%) had mor-
phological or functional changes detected
by two-dimensional Doppler echocardiogra-
phy.
Methods
Serum iron, total iron-binding capacity,
transferrin saturation, plasma ferritin, and
Table 2. Assessment of the cardiac function of thalassemia patients.
Patient No. Chest X-ray Electrocardiogram at rest 2-D Doppler echocardiogram
1 Normal Normal Normal
2 Normal Normal Normal
3 Normal Normal Normal
4 Normal Normal Normal
5 Normal Normal Normal
6 Normal Normal Normal
7 Normal Normal Normal
8 Normal Normal Normal
9 Normal Normal Normal
10 Normal Normal Global cardiac enlargement +
11 Cardiomegaly ++ DAVR and LVO Global cardiac enlargement ++,
diffuse LV hypokinesia ++,
depressed LV systolic function,
and mitral regurgitation +
12 Normal Normal LA enlargement +
13 Normal Normal Normal
14 Normal Normal Normal
15 Normal Normal Normal
16 Normal Normal LA enlargement +
17 LV enlargement LVO Global cardiac enlargement +,
and diffuse LV hypokinesia +
18 Normal Normal Normal
19 Cardiomegaly + DAVR and LVO LA and LV enlargement ++
20 Normal DAVR and LVO Global cardiac enlargement +
21 Normal DAVR Normal
22 Cardiomegaly ++ DAVR, HFAF, and LA, LV and RV enlargement ++,
low QRS amplitude tricuspid regurgitation ++,
and diffuse LV hypokinesia ++
23 Normal  1st grade RBB LA and LV enlargement +
24 Cardiomegaly ++ LAO and LVO LA and LV enlargement +, and
mitral regurgitation +
25 Normal DAVR Normal
26 LV enlargement Normal Normal
LV: left ventricle; DAVR: diffuse abnormalities of ventricular repolarization; LVO: left
ventricle overload; HFAF: high frequency atrial fibrillation; RBB: right branch block;
LAO: left atrium overload; LA: left atrium; RV: right ventricle; +: discrete; ++: moder-
ate.
urinary iron. Serum iron, total iron-binding
capacity and transferrin saturation were meas-
ured by the alpha-dipyridyl method (18,19).
Plasma ferritin was determined using an im-
munoenzymatic method (Ferrizyme kit,
Abbott Laboratories, Chicago, IL, USA).
Urinary iron excretion was measured within
24 h after urinary collection (4 to 6 samples
per patient, except for one patient who had
only two samples) by the bathophenanthro-
line colorimetric method (20,21).
Daily and annual urinary iron excretion.
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The daily urinary iron loss was estimated
from the urinary iron measurement. Since
DF was used 5 days a week, the average
urinary iron excretion of each patient, meas-
ured on the days when they applied the
subcutaneous chelator at home, was multi-
plied by 5/7. The annual urinary iron excre-
tion was obtained by multiplying the average
daily excretion by 365.
Total and annual weight of red cells trans-
fused. Patients were transfused with packed
red cells. The hematocrit of 38 units of red
cell concentrates obtained at the time of
transfusion was 0.85 ± 0.063 (mean ± SD).
The weight of red cells transfused annually
was calculated from this value and averaged
over the three-year period. Retrospective data
were retrieved from the blood bank files to
calculate the total amount of red cells re-
ceived by the patient over his whole life.
Daily and annual parenteral iron gains,
and total transfusional iron. Daily and an-
nual parenteral iron gains and total transfu-
sional iron load were calculated from the
weight of red cells transfused, since 1 ml of
red cells contains approximately 1 mg of
iron (3).
Fecal iron excretion. Measurement of
fecal iron excretion was not performed in the
present study. The literature data are scarce
and ranged from 10 to 50% of the urinary
excretion with an intramuscular or subcuta-
neous DF dose of 500 mg or 20 mg/kg in 21
patients with iron overload (22-27), and from
49 to 65% for DF administered intravenously
to four iron-overloaded patients (27). Thus,
to calculate iron balance, we used the aver-
age obtained from the extreme values of 10
to 50% total iron excreted into the feces.
Annual iron balance. The annual iron
balance was calculated from the daily paren-
teral iron gain (via transfusions), minus the
measured urinary iron losses and the esti-
mated biliary loss (fecal excretion). Gas-
trointestinal iron absorption was not taken
into account since it is minimal under these
conditions (3,28).
Clinical severity grades. Each patient was
allocated to a clinical grade group on the
basis of the clinical severity of the disease,
evaluated by the following criteria: i) car-
diac manifestations: absence of changes, 0
point; presence of cardiac heart failure, 1
point; changes in resting electrocardiogram,
1 point; image changes (2-D Doppler echo-
cardiogram or chest X-ray), 1 point; ii) endo-
crine manifestations: absence of changes, 0
point; glucose intolerance or diabetes melli-
tus, 1 point; iii) hepatic manifestations: ab-
sence of changes, 0 point; increase of serum
ALT, 1 point.
High-dose intravenous chelation. Four-
teen patients aged >12 years were submitted
to a protocol for intensive iron chelation
with continuous intravenous infusion of DF
during hospitalization consisting of the fol-
lowing steps: a) daily, 24-h urine collection
for determination of urinary iron excretion;
b) on the first day, no medication was given
so that basal urinary iron excretion could be
determined; c) on the second day, the patient
received a standard “bolus” dose of 0.5 g DF
intramuscularly together with 100 mg vita-
min C per os; d) on the subsequent days, the
patient received increasing doses of 3, 6 and
9 g DF in 2 liters of 0.9% saline, given as a
continuous 24-h intravenous infusion, to-
gether with a 100 mg oral supplement of
vitamin C; e) each DF dose was used for 1-4
days before increasing to the next level; f)
during hospitalization, close clinical moni-
toring was carried out, especially for oph-
thalmic, audiologic and pulmonary compli-
cations.
Statistical analysis
Nonparametric methods were used for
statistical analysis of the results: Spearman
correlation coefficient, Mann-Whitney rank
sum test and Fisher’s exact test. Logistic
regression (multivariate analysis) was used
to evaluate the possible effects of the rel-
evant variables as a whole.
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Results
Results of the iron balance studies for 26
patients are summarized in Table 3. Serum
iron concentrations ranged from 161.5 to
289.0 µg/dl (median 193.5). Transferrin satu-
ration ranged from 64.7 to 99.7% (median
88.6) and was correlated positively with pa-
tient age (r = 0.508, P<0.01). The individual
mean plasma ferritin values (averages of 2-4
measurements per patient) ranged from 1,536
to 13,525 ng/ml (median 3,787). There was a
significant correlation of plasma ferritin with
age (r = 0.458, P<0.05) and with ALT (r =
0.400, P<0.05). Daily urinary iron excretion
induced by subcutaneous DF at home ranged
from 4.9 to 48.3 mg/24 h (median 15.1).
These values correlated positively with pa-
tient age (r = 0.468, P<0.05) and with plasma
ferritin levels (r = 0.472, P<0.05). The aver-
age excretion obtained with subcutaneous
DF was significantly higher in patients with
clinical grades III to V than in patients with
grades 0 to II (P<0.05). The total transfu-
sional iron gain ranged from 0.18 to 2.27
g/kg body weight (median 0.99). There was
a significant positive correlation of transfu-
sional iron gain with plasma ferritin levels
(r = 0.517, P<0.01). The individual average
value of the annual balance corrected for
body weight ranged from -0.25 to 0.09 g/kg
body weight (median 0.0027) (Table 3).
There was a negative correlation between
annual balance and plasma ferritin levels (r =
-0.405, P<0.05). Patient classification into
grades of clinical severity presented a sig-
Table 3. Iron distribution in thalassemic patients after subcutaneous deferoxamine (DF) administration at home.
Patient Age Follow-up Serum iron Transferrin Plasma ferritin Urinary iron Corrected transfusion Corrected
No. (years) (years) (µg/dl) saturation (ng/ml) (mg/24 h) total iron gain average iron annual
(%) (g/kg)1 balance (g kg-1 year-1)1
1 4 3 182.0 96.0 1,536 7.26 0.53 0.021
2 4 4 202.0 76.2 3,046 11.93 0.73 -0.050
3 5 2 170.5 69.2 1,627 5.74 0.58 0.093
4 5 2 271.0 89.4 2,973 17.87 0.45 -0.164
5 6 6 185.5 81.5 3,430 6.77 1.01 0.067
6 6 4 196.3 68.8 2,890 4.90 0.72 0.067
7 9 2 174.0 84.5 1,835 9.91 0.44 0.024
8 10 9 169.5 69.3 3,819 9.65 1.46 0.040
9 10 9 289.0 92.6 2,211 9.28 1.15 0.061
10 12 6 176.5 73.7 3,759 20.35 1.09 -0.003
11 13 12 190.7 64.7 5,017 24.50 1.56 -0.100
12 13 12 246.5 96.5 13,525 15.31 1.72 -0.032
13 13 9 190.5 97.0 3,994 18.97 1.36 -0.016
14 13 11 183.0 86.5 7,011 12.04 1.63 0.084
15 14 4 184.5 93.2 3,699 19.25 0.75 -0.028
16 14 7 199.0 88.0 3,957 15.10 1.25 -0.007
17 15 13 210.9 87.7 1,950 8.73 1.42 0.084
18 16 4 248.5 96.4 4,375 48.35 0.64 -0.252
19 17 0.5 185.0 98.4 3,816 - - -
20 19 1 161.5 89.0 5,512 18.19 0.18 -0.012
21 20 18 227.3 96.5 4,092 23.42 1.98 -0.056
22 21 19 270.0 95.8 5,356 29.30 2.27 -0.079
23 21 4 265.0 82.4 1,797 19.91 0.76 0.007
24 25 4 270.5 97.3 1,746 10.97 0.72 0.059
25 28 11 186.7 99.7 5,756 8.73 1.03 0.051
26 50 12 219.3 88.3 6,400 17.43 0.98 -0.006
Patients received 20 to 60 mg DF/day for 8 to 12 h daily.
1kg body weight.
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Table 4. Comparison of the major clinical and laboratory data of compliant and non-compliant patients treated
with deferoxamine (DF).
Compliant Non-compliant
Patients (N) 17 9
Age (years) 4-24 (10)1* 13-50 (19)
Diabetes or glucose intolerance 3/172 1/9
Elevated ALT 7/17 7/9
Cardiac abnormality 5/17* 8/9
Serum iron (µg/dl) 169.5-289.0 (196.3) 161.5-270.0 (190.7)
Transferrin saturation (%) 68.8-97.3 (87.7) 64.7-99.7 (95.8)
Plasma ferritin (ng/ml) 1,536-4,375 (2,973)* 3,816-13,525 (5,512)
Total iron gain (g/kg) 0.44-1.46 (0.75)* 0.18-2.27 (1.59)
Annual iron balance (g kg-1 year-1) -0.252-0.093 (0.024) -0.100-0.084 (-0.022)
Urinary iron excretion (3 g DF sc) (mg/24 h) 4.9-48.3 (11.9) 8.7-29.3 (17.8)
Urinary iron excretion (6 g DF im) (mg/24 h) 3.8-12.5 (6.2) 5.2-17.1 (8.5)
Urinary iron excretion (9 g DF iv ) (mg/24 h) 49.4-58.5 (53.1)* 52.5-163.2 (76.6)
Increase of urinary iron excretion (mg/24 h)3 -5.9-25.1 (20.0)* 4.2-78.1 (41.0)
1Data are reported as range (median) except for 2affected patients/total patients. 3When the intravenous DF
dose was increased from 3 to 9 g/day. NS: not significant; ALT: alanine aminotransferase.
*P<0.05 compared to non-compliant patients (Mann-Whitney rank sum test).
nificant positive correlation with age (r =
0.695, P<0.001).
The proportion of compliant patients was
higher among patients with clinical grades 0
to II than among patients with grades III to V
(P<0.05). Table 4 displays the comparison
of the main clinical and laboratory data be-
tween compliant and non-compliant patients
under DF therapy. Patients classified as non-
compliant were older than compliant pa-
tients (P<0.01), and included a higher pro-
portion of cardiac abnormalities (P<0.01).
Plasma ferritin levels were significantly
higher in the group of non-compliant pa-
tients than in the compliant group (P<0.01).
The compliant patients presented a lower
transfusional iron load than the non-compli-
ant patients (P<0.05).
A subgroup of 14 patients, 8 males and 6
females, ranging in age from 13 to 50 years
(median 16.5), was submitted to intensive
iron chelation with intravenous DF for 8 to
14 days (median 12). The urinary iron excre-
tion induced by a single “bolus” intramuscu-
lar injection of 0.5 g DF ranged from 3.8 to
17.1 mg/24 h (median 8.4), and no correla-
tion was observed with clinical grade, com-
pliance or patient age. The excretion in-
duced by continuous intravenous injection
of DF at the doses of 3, 6 and 9 g/24 h ranged
from 24.4 to 89.6 mg/24 h (median 37.3),
from 16.8 to 136.9 mg/24 h (median 55.9),
and from 49.4 to 163.2 mg/24 h (median
61.3), respectively (Figure 1). The average
excretion obtained with 6 and 9 g DF was
significantly higher in patients with clinical
grades III to V compared to patients with
grades 0 to II (P<0.05 for both concentra-
tions). At the dose of 9 g DF, the urinary iron
excretion was significantly higher in non-
compliant patients than in the compliant
group (P<0.01). No side effect was detected
as a result of DF use, either in the chronic
chelation therapy or in the high-dose chela-
tion approach.
The increase in urinary iron excretion
obtained with 6 g DF over the excretion
obtained with 3 g DF ranged from -7.60 to
51.80 mg iron/24 h (median 16.9), whereas
the increase in urinary iron excretion ob-
tained with 9 g (maximum dose) of DF as
compared with excretion obtained with 3 g
(minimum dose) of DF ranged from -5.9 to
78.1 mg iron/24 h (median 28.7) (Figure 2).
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These differences presented a significant
positive correlation with the total transfu-
sional iron gain corrected for body weight
(r = 0.566, P<0.05 for 6 g DF and r = 0.630,
P<0.05 for 9 g DF, respectively) and the
clinical severity grades (P<0.05 for both).
For the 9 g DF infusion, the non-compliant
group presented a larger difference between
the iron excretion achieved by the maximum
and minimum intravenous DF doses than the
compliant group (P<0.05).
Multivariate analysis indicated that the
only variable able to predict compliance was
plasma ferritin: levels >4,100 ng/ml pre-
sented a negative correlation with compli-
ance (OR = 0.18, 95% CI: 0.001-0.231, P =
0.002). A parameter that predicted clinical
severity was the increase in urinary iron
excretion obtained with 9 g DF as compared
with the excretion obtained with 3 g DF:
levels >28.5 mg/24 h presented a positive
correlation with clinical grade (OR = 15.0,
95% CI: 1.03-218, P = 0.047).
Urinary iron excretion during intensive
chelation therapy induced by a total of 45 to
90 g intravenous DF over a period of 6 to 12
days ranged from 0.25 to 1.77 g iron (median
0.54). These values correspond to 4.1 to
22.4% (median 7.5) of the iron accumulated
by transfusion in one year (Table 5).
Discussion
The present study was performed on pa-
tients with a well-defined and heterogeneous
clinical profile that allowed the comparison
between non-compliant patients with a more
severe clinical picture, indicated by a higher
clinical grade, and the compliant group with
a lower clinical grade.
At present, iron overload can be evalu-
ated by several direct or indirect methods
(1,21,29). Measurement of iron concentra-
tion in hepatic tissue obtained by biopsy is a
more accurate indicator of the grade of tissue
iron overload (21,29,30). However, it is an
invasive procedure subject to specific indi-
Figure 1. Effect of intravenous
deferoxamine dose on thalas-
semic patients. Each line cor-
responds to the mean excre-
tion rate of one patient who
received 3, 6, and 9 g of the
chelator for 1-4 days before
the dose was changed.
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Figure 2. Increase of urinary iron
excretion induced by 6 and 9
g/day of intravenous deferox-
amine in relation to the excre-
tion obtained with 3 g/day. Each
line corresponds to the mean
excretion caused by the dose of
chelator for one patient. The av-
erage value (mean ± SEM) for
the urinary iron/24 h for all pa-
tients with 3 g deferoxamine/24
h was 44.52 ± 20.20 mg.
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cations. Magnetic resonance of liver and
heart is also used for evaluation of iron
overload (7,29). As an alternative, we used
the clinical complications arising from the
excessive tissue iron, the total amount of
transfusional iron accumulated over the years
corrected for body weight and compliance
with chelation therapy as indicators of the
grade of iron overload. The data on total
transfusional iron gain derived from the trans-
fusion records showed a large iron overload,
which, for many patients, exceeded the le-
thal threshold of 1 g iron/kg body weight
(28). In spite of this huge iron input over the
years, all but two patients remain alive, a
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clear indication of the protection afforded by
chelation with DF.
Several indirect approaches have been
analyzed in this study to identify the best
indicator of overload severity. First, our re-
sults show that serum iron concentration and
transferrin saturation, even though high in
these patients, do not distinguish amongst
the various grades of overload. The annual
iron balance corrected for body weight also
proved to be of limited value. Plasma ferritin
level appears to be a better indicator, but
grossly increased levels may be observed as
a consequence of significant hepatic injury
(31,32).
Urinary iron excretion induced by subcu-
taneous DF (20-60 mg/kg body weight) at
home showed a positive correlation with the
clinical grade. Urinary iron excretion after a
single intramuscular injection of 0.5 g DF is
traditionally used either as an indirect meas-
urement of iron overload or as a diagnostic
Table 5. Overall data from intensive chelation therapy with intravenous deferoxamine (DF) during hospitaliza-
tion.
Patient Age Annual iron acquired Urinary iron Total days of Total dose of
No. (years)  by transfusion excreted during iv DF during DF during
(g)  hospitalization hospitalization hospitalization
    (g)
(g) (%)1
11 13 5.95 0.63 10.6 9 60
12 13 5.26 0.39 7.4 7 54
13 13 7.06 0.59 8.3 10 62
14 13 8.08 0.69 8.5 10 63
15 14 6.65 0.50 7.5 10 66
17 15 7.74 0.32 4.1 7 54
18 16 7.28 0.32 4.4 6 45
19 17 - 1.10 - 8 54
20 19 6.80 0.50 7.3 9 54
21 20 6.85 0.63 9.2 10 63
22 21 7.90 1.77 22.4 12 90
23 21 8.43 0.47 5.6 10 66
25 28 6.05 0.25 4.1 6 45
26 50 6.75 0.70 10.4 10 72
1Iron excreted as percentage of the amount of iron acquired annually.
Table 6. Summary of statistical significance of iron metabolism measurements for the patients grouped by
clinical grade or by compliance with the treatment.
Clinical grade Compliance
Serum iron NS NS
Transferrin saturation NS NS
Plasma ferritin NS S
Total iron gain NS S
Annual iron balance NS NS
Urinary iron excretion (3 g DF sc) S NS
Urinary iron excretion (6 g DF im) NS NS
Urinary iron excretion (9 g DF iv) S S
Urinary iron excretion increase S S
S = statistically significant, NS = not significant by the Mann-Whitney rank sum test, with the level of
significance being P<0.05.
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test for primary hemochromatosis (28,33).
Our data demonstrate that this test may be
useful to distinguish between the presence
or absence of iron overload, but it is not
sufficiently sensitive to identify differences
between individuals with heterogeneous iron
overloads. Thus, even though the urinary
iron excretion induced by the continuous use
of 3 g intravenous DF over a 24-h period
increased considerably, it did not signifi-
cantly correlate with other variables that in-
dicate a more severe iron overload. How-
ever, when excretion was induced by 6 g of
intravenous DF, urinary iron excretion was
higher in patients with clinical grades III to
V, and when it was induced by 9 g DF, it was
significantly higher both in non-compliant
patients and in patients with higher clinical
grades (Table 6).
The increase of iron excretion induced by
larger doses of intravenous DF, measured by
the difference between the urinary excretion
induced by infusion of 6 or 9 g DF and that
obtained with 3 g DF, was an efficient method
to distinguish amongst the various degrees of
iron overload: the differences (when calcu-
lated as the absolute increase over the excre-
tion induced by 3 g) were significantly higher
for the patients with the higher clinical severity
grades and for those with the higher transfu-
sional iron gain corrected for body weight.
The difference between compliant and non-
compliant patients was demonstrable only with
the increase of iron excretion obtained when
the amount of DF was increased from 3 to 9 g
daily. These observations support the view
that the amount of potentially chelatable iron
is proportional to the extent of overload and
that, in a population of massively overloaded
patients, urinary iron excretion is an efficient
indirect indicator of the extent of iron overload
only when it is induced by high doses of
intravenous DF.
Finally, we evaluated the efficiency of
the more intensive chelation with continu-
ous intravenous DF as an accessory thera-
peutic approach for ß-thalassemia homozy-
gote patients. Iron excreted into urine during
a 6- to 12-day period of hospitalization using
this treatment corresponds to a median of
7.5% (reaching a maximum of 22.4%) of the
amount of iron received by transfusion dur-
ing one year. However, since the amount of
iron excreted into the feces can exceed 50%
of the total losses (27), total excretion prob-
ably reaches a maximum of 44.8% and a
median value of 15.0%. It is necessary to
emphasize the low accuracy of this value
since the only value directly measured was
daily urinary iron excretion, whereas the
other components were only estimated. If
the chelation period is prolonged, the effec-
tiveness of this approach could be even
greater, especially for patients with high iron
overloads. It remains to be demonstrated
that the iron mobilization, obtained under
these conditions in persons with important
tissue injuries, is efficient in preventing the
evolution of secondary hemochromatosis.
Our results, however, suggest that this ap-
proach can be a therapeutic tool for patients
with large iron overloads, in addition to che-
lation with subcutaneous DF carried out at
home since the maintenance of high-dose
infusions over a period of several days a year
can effectively cause the excretion of sig-
nificant amounts of iron. However, life-
threatening pulmonary complications of this
treatment have been reported (34,35), as
well as possible auditive and ophthalmic
adverse effects (6,29), which should be con-
sidered when planning individual treatments.
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